Lowdep (Citalopram)

Quick links

Choose a section

Quick links to important sections

Advertisements

Lowdep (Citalopram)

Advertisements
Advertisements

Treatment option: Depression, Neurosis

Advertisements

Overview of Lowdep (Citalopram)

Lowdep is a prescription medicinal agent whose active component is the International Nonproprietary Name (INN) substance Citalopram, utilized primarily to help manage mood and emotional stability in adults. The substance is chemically synthesized as a racemic bicyclic phthalane derivative, confirming its status as a man-made compound. It is formally established as an antidepressant and belongs specifically to the class known as Selective Serotonin Reuptake Inhibitors (SSRIs).

Property Description
Active Ingredient Citalopram (hydrobromide)
Form Oral Tablet, Oral Solution
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Therapeutic Aim Stabilization of mood and emotional state
Origin Synthetic, Single-agent product

What Type of Medicine is Lowdep (Citalopram)?

Citalopram is classified as an SSRI, a major group of psychoanaleptic agents. This classification is based on the compound’s potent ability to inhibit the neuronal reuptake of the neurotransmitter Serotonin (5-HT) in the central nervous system. Citalopram is clinically recognized for its high functional selectivity for the Serotonin Transporter (SERT), which is a key differentiator from older, less-selective antidepressants. It is globally recognized as a core therapeutic agent.

What is the Active Ingredient and Form of Lowdep?

The sole active ingredient in this single-agent product is Citalopram, frequently formulated as its hydrobromide salt. The medication is prepared for oral administration and is supplied in pharmaceutical forms, including film-coated tablets and an oral solution. Citalopram is chemically a racemic mixture, meaning it contains both the (R)- and (S)-enantiomers, although pharmacological studies attribute the majority of the substance's therapeutic activity to the (S)-enantiomer. The oral solution form offers a specific benefit for patients who may encounter difficulty swallowing tablets.

What is the Therapeutic Aim of a Selective Serotonin Reuptake Inhibitor?

The primary therapeutic aim is to restore neurochemical equilibrium by potentiating serotonergic activity, which is crucial for regulating emotional well-being. By blocking the reabsorption of Serotonin, the drug increases the concentration of this essential chemical messenger in the synaptic space. This action helps support the stabilization of mood and emotional state, which is the general therapeutic goal when managing conditions characterized by persistent emotional distress.

Regulatory References

  1. Citalopram: MedlinePlus Drug Information
Advertisements

What side effects are possible with Lowdep (Citalopram)?

Possible Side Effects and Safety Information

The officially documented adverse effects of Citalopram are categorized by frequency and the body system affected, providing a structured understanding of its safety profile according to regulatory standards (e.g., EMA and FDA).

Commonly Classified Adverse Reactions: Adverse reactions classified as Very Common (occurring in ge 1/10 people) often include headache, nausea, dry mouth, and increased sweating. Reactions classified as Common (ge 1/100 to < 1/10) include insomnia, dizziness, tremor, diarrhea, constipation, fatigue, and sexual dysfunction.

Serious Adverse Reactions and Constraints: Regulatory documents highlight several serious risks. Citalopram is associated with dose-dependent QT-interval prolongation, which is a measure of the heart's electrical activity. This risk can lead to potentially fatal heart rhythm abnormalities, such as Torsades de Pointes. Citalopram is formally contraindicated in individuals with congenital long QT syndrome or those taking other medicines known to prolong the QT interval.

Other serious documented risks include the potential for Serotonin Syndrome, a systemic condition, and Hyponatremia (low blood sodium levels), which has been predominantly reported in older adults.

Safety Patterns and Special Populations: The official safety information notes that the risk of suicidal ideation and behavior is highest during the initial phases of therapy and following dose adjustments. Furthermore, specific constraints apply to certain patient groups: the maximum dose is restricted for older adults (typically ge 60 years of age) and patients with hepatic impairment due to the increased risk of high Citalopram exposure and subsequent QT prolongation. Discontinuation of treatment may lead to officially documented withdrawal reactions, emphasizing the need for regulatory-defined cessation procedures.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose information for Citalopram is strictly defined in government regulatory labeling, specifying both clinical manifestations and mandated emergency actions.

Documented Manifestations and Severe Outcomes

Official documents state that overdose may result in central nervous system effects such as seizures, confusion, somnolence, tremor, and agitation. Gastrointestinal symptoms including nausea and vomiting are also documented. The most severe outcomes are dose-dependent QTc prolongation and the risk of the fatal cardiac arrhythmia, Torsade de Pointes. Serotonin Syndrome, a severe nervous system reaction, is also cited as a potential complication requiring urgent response.

When and How to Seek Help

Regulatory labeling mandates that individuals seek immediate medical attention for any suspected overdose. Emergency services must be contacted immediately if collapse, a seizure, trouble breathing, or signs of an abnormal heart rhythm are observed. No specific antidote is known for Citalopram; therefore, the official treatment approach is symptomatic and supportive. This requires continuous ECG monitoring to assess the QTc interval and heart function, along with electrolyte monitoring to correct imbalances. Regulatory sources note that elderly patients and those with hepatic impairment carry an increased risk of severe cardiac toxicity in overdose situations.

Advertisements

Therapeutic Uses of Lowdep (Citalopram)

What Lowdep (Citalopram) Treats: Main Uses and Benefits

Citalopram is an oral prescription medication that is commonly used to help with symptomatic relief across multiple therapeutic domains, relevant when symptoms create noticeable interference with daily stability and comfort. It may be part of symptomatic management for conditions such as Major Depressive Disorder, Panic Disorder, and Premenstrual Dysphoric Disorder (PMDD).

It is applied in clinical settings that involve acute or disruptive symptom patterns, often used during phases when symptoms become more noticeable. It is commonly used to help address symptom clusters that include persistent sadness, excessive worry, and related issues like sleep disturbances and fatigue.

“This medication is relevant for easing symptoms related to heightened physiological activity and can contribute to easing the overall symptom load associated with difficult episodes.”

By supporting emotional stability and managing the intensity of difficult symptoms, Citalopram may assist with maintaining functional stability in routine activities and contributes to improved comfort during symptomatic periods.

Quick Fact: Support for Excessive Worry Citalopram may assist in managing the severity and frequency of difficult-to-control worry and sudden, intense panic attacks.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Official Eligibility for Lowdep (Citalopram)

Lowdep (Citalopram) is officially approved for use in Adults (generally 18 years and older). Regulatory agencies define specific populations who are restricted or prohibited from using the medication, primarily due to cardiac and drug interaction risks.


Absolute Contraindications

Use is formally prohibited in patients with:

  • Pre-existing QT-interval prolongation or congenital long QT syndrome.
  • Concurrent use of Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, or within 14 days of discontinuing an MAOI.
  • Concurrent use of pimozide or other medicinal products known to prolong the QT-interval.

Restricted and Non-Approved Populations

Population Group Regulatory Status and Constraint
Pediatric Patients (under 18) Not approved; use is not established.
Geriatric Patients (over 60/65) Use is restricted to a lower maximum daily dose (e.g., 20 mg/day).
Hepatic Impairment Requires a restricted maximum daily dose (e.g., 20 mg/day).
Severe Renal Impairment Use is not established; caution is advised.

Eligibility is also conditional for patients with uncorrected electrolyte imbalances, unstable epilepsy, and during pregnancy or breastfeeding, where caution and monitoring are mandatory as per official labeling.

Advertisements

What should I know about interactions with other medicines?

Lowdep (Citalopram) Interactions with other medicines and products

The interaction profile of Citalopram is defined by specific restrictions and constraints documented by governmental regulatory authorities.

Contraindicated Combinations

Co-administration with the following medicinal products is formally contraindicated:

  • Monoamine Oxidase Inhibitors (MAOIs): Including MAOIs used for psychiatric disorders, Linezolid, and Intravenous Methylene Blue. A mandatory 14-day period must elapse between discontinuing Citalopram and starting an MAOI, or vice-versa, due to the risk of Serotonin Syndrome.
  • Pimozide and other Medicinal Products that Prolong the QT-interval: Prohibited due to the risk of potentially serious effects on heart rhythm.

Other Documented Interactions

Interaction Type Interacting Substances (Examples) Official Regulatory Constraint
Serotonergic Risk Triptans, Tricyclic Antidepressants, Lithium, St. John's Wort May increase the risk of Serotonin Syndrome. Co-use with St. John's Wort is not advised in official documents.
Bleeding Risk NSAIDs, Aspirin, Warfarin, other antiplatelet agents Concomitant use increases the risk of bleeding events.
Pharmacokinetic Strong CYP2C19 Inhibitors (e.g., Omeprazole) May decrease Citalopram clearance, which is a factor in dose restrictions for certain populations.

Population and Product Notes

The official interaction profile notes that patients with hepatic impairment, those older than 60 years, and individuals identified as CYP2C19 poor metabolizers exhibit reduced clearance and are cited for specific dosage limitations. Co-administration with alcohol is generally not recommended in the regulatory documents.

Advertisements

Mechanism of Action

Selective Targeting of the Serotonin Transporter

The drug's primary mechanism is the specific and selective inhibition of the Serotonin Transporter (SERT) (SLC6A4), a protein that reabsorbs the neurotransmitter Serotonin (5-HT) from the synaptic cleft. This targeted action is primarily driven by the (S)-enantiomer and results in the functional effect being tightly focused on increasing the concentration of Serotonin available to post-synaptic receptors.


⏱️ Time-Dependent Neurotransmitter Recalibration

The immediate increase in Serotonin initiates a critical secondary cascade involving the gradual desensitization and down-regulation of inhibitory 5-HT1A autoreceptors on the presynaptic neuron. This delayed cellular adaptation releases a functional brake on Serotonin release, leading to a progressive, sustained enhancement of serotonergic signaling across the brain's affective and limbic circuits.


Modulation of Affective and Stress-Response Circuits

The sustained, enhanced Serotonin neurotransmission modulates critical brain regions, including the amygdala and prefrontal cortex, which are components of the central nervous system's affective circuitry. This mechanism involves the modulation of pathways within the affective and stress-response systems, which alters the functional output of neurological circuits that govern central processing.

Advertisements

Dosage and Administration Information

How Lowdep (Citalopram) is Used

Citalopram is administered as a single daily oral dose, available as film-coated tablets or an oral solution for patients. The medication may be taken with or without food because absorption is not affected by meal intake. Administration is flexible and can occur in either the morning or the evening, but should be at a consistent time each day to support adherence.


Standard Dosing and Titration

For the general adult population, the therapy protocol typically begins with a starting dose of 20 mg of citalopram once daily. The dose may be increased, but any adjustment must be gradual, requiring a minimum of one week between changes. The maximum recommended dose for general adult use is strictly limited to 40 mg once daily.


Administration for Specific Groups

Lower maximum daily doses are established for certain patient populations to limit drug exposure:

Patient Group Maximum Recommended Dose (Daily)
Older Adults (Age 60 or 65 and older) 20 mg once daily
Hepatic Impairment 20 mg once daily
CYP2C19 Poor Metabolizers 20 mg once daily

No specific dosage adjustment is typically required for patients presenting with mild to moderate renal impairment.


Duration and Discontinuation

Treatment often involves an acute phase (reviewed within 3 to 4 weeks) followed by a maintenance phase, which commonly continues for at least six months after initial improvement. When therapy is concluded, the dose must be gradually reduced (tapered) over a period of at least one to two weeks, as abrupt cessation is not advised.

Advertisements

Recent Clinical Evidence

Lowdep (Citalopram): Recent Clinical Evidence

Overview of Approved Use

Lowdep is the trade name for the active ingredient citalopram, an FDA-approved medication classified as a selective serotonin reuptake inhibitor (SSRI). Citalopram is indicated for the treatment of major depressive disorder (MDD). It is believed to work by increasing the concentration of serotonin in the brain, though the precise mechanism leading to therapeutic effects is still being explored.

Evidence Base for MDD

Clinical research supporting the use of citalopram for MDD includes multiple randomized, double-blind, placebo-controlled trials. These studies have evaluated the compound's effect on various standardized measures of depression severity, such as the Hamilton Depression Rating Scale (HDRS).

Findings consistently show that treatment with citalopram is associated with a reduction in mean depression symptom scores compared to placebo in adults diagnosed with MDD. While individual responses vary, the observed effects typically emerge over several weeks of continuous administration, aligning with the pattern commonly associated with SSRI class medications.

Safety and Tolerability Summary

Citalopram has been studied extensively regarding its side effect profile. Like all medications, it is associated with potential side effects, which are generally categorized as mild to moderate in severity. The most commonly reported adverse events during trials include nausea, dry mouth, sleepiness, and increased sweating. These are often transient, meaning they may lessen or resolve as treatment continues.

Clinical studies have also evaluated specific risks associated with citalopram, particularly the potential for QT interval prolongation, a change in the heart's electrical activity. Due to this potential effect, regulatory bodies recommend limits on daily dosage to mitigate the risk, especially in certain patient populations.

Key Studies & References

  1. Citalopram - StatPearls (Source for indication, class, and general pharmacokinetics)
  2. Citalopram and escitalopram: QT interval prolongation (UK Regulatory guidance)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Lowdep (Citalopram) (FAQ)

Q: Is it typical to feel slightly worse or have increased side effects during the first one or two weeks of Citalopram use?

Official documents note that during the initial months of treatment, especially in patients age 24 and younger, worsening of depression or changes in behavior is required to be monitored closely. The risk of worsening symptoms and suicidal ideation is noted to be highest during the initial treatment phases or following a change in dose. Official documents describe the need to watch for and report any concerning changes.


Q: Are there any specific foods or drinks that should be avoided when taking Citalopram?

Regulatory documents state that Citalopram may be taken with or without food, meaning there are no required food restrictions. However, official information describes alcohol use as generally not recommended for patients being treated for depression.


Q: How does Citalopram interact with certain prescription medicines used for migraine headaches?

Official warnings describe the need for caution when Citalopram is used together with other serotonergic drugs, such as triptans used for migraines. This is due to an increased risk of a serious condition called Serotonin Syndrome. Careful observation by a professional is required, particularly when starting treatment or changing doses.


Q: What is the safety information regarding Citalopram use in pregnant or breastfeeding women?

Official product information states that use is conditional during pregnancy, based on whether the expected benefit is greater than the potential risk to the fetus. Newborns exposed to SSRIs late in the third trimester have uncommonly reported clinical findings, such as breathing difficulties and irritability. A specialized pregnancy exposure registry exists to monitor outcomes for those exposed.


Q: Is Citalopram commonly prescribed to older adults (seniors)?

Citalopram is used in older adults, but official guidelines require a restricted maximum daily dose of 20 mg for individuals aged 60 or 65 and over. This restriction is primarily due to a heart-related side effect called QT prolongation. Older adults are also noted to be at a higher risk for developing low blood sodium levels (hyponatremia).


Q: Is Citalopram considered a physically addictive substance?

Regulatory sources use the term discontinuation syndrome to describe the physical reaction that can occur if the medication is stopped suddenly. Symptoms of discontinuation can include dizziness, agitation, and anxiety. Official instructions detail a required gradual reduction (tapering) process over time rather than abrupt cessation.


Q: Does Citalopram affect a person's ability to drive or perform tasks that require alertness?

Official product information notes that Citalopram has the potential to impair thinking, judgment, and motor skills. This information contains a caution regarding operating hazardous machinery, including driving, until a person is reasonably certain they do not experience these adverse effects.


Q: Is Lowdep used to treat conditions other than major depression?

Citalopram’s primary indication in the US is Major Depressive Disorder (MDD). However, some international documents note that Citalopram is also approved for the treatment of other anxiety-related conditions, such as Panic Disorder or Obsessive Compulsive Disorder.


Q: Do people typically gain weight when using Citalopram?

Clinical trial data indicates that changes in body weight (both gain and loss) are possible while using Citalopram. Studies noted that the overall weight change observed in the population was minimal, and in some cases, a small amount of weight loss was seen. Individual experiences with weight change can vary.


Q: Can Citalopram cause mental effects like 'brain fog' or difficulty concentrating?

Official safety information indicates that Citalopram may interfere with cognitive performance. Reports from patients after the drug was marketed have included difficulty with thinking, concentration, and memory.


Q: Can Citalopram cause increased feelings of anxiety when a person first starts taking it?

Official guidelines describe the need for patients and caregivers to monitor for and report the emergence of symptoms such as extreme worry, agitation, and panic attacks during the early stages of treatment. These specific symptoms are consistent with increased anxiety.


Q: What are the described signs of a serious, sudden allergic reaction to Lowdep?

Regulatory documents confirm that severe allergic reactions, such as angioedema (swelling beneath the skin) and anaphylaxis, have been reported. Signs of such a reaction include swelling of the face, tongue, mouth, or throat, hives, and trouble breathing or swallowing.


Q: How long does the Citalopram substance generally remain in the body after the last dose is used?

According to pharmacokinetic data, the average half-life of Citalopram is approximately 35 hours. This means it takes about six to seven days for the substance to be mostly cleared from the body. The half-life can be longer in specific populations, such as older adults or those with impaired liver function.


Q: Are there specific cold or flu medicines that contain ingredients that interact with Citalopram?

Official warnings indicate the need for careful use with cold and flu medicines. Ingredients like the cough suppressant dextromethorphan may increase the risk of Serotonin Syndrome. Additionally, sympathomimetic agents, which are found in some decongestants, are noted for potential cardiovascular effects.


Q: Is there an interaction risk between Citalopram and over-the-counter cough suppressants?

Yes, official warnings note a potential interaction with certain cough suppressants. Cough suppressants that contain the ingredient dextromethorphan can increase the risk of a serious condition called Serotonin Syndrome when combined with Citalopram.


Q: How does the action of Citalopram on serotonin compare to that of its close relative, Escitalopram?

Regulatory safety updates explain that Citalopram is chemically a racemic mixture. This means it contains both the active (S-) and inactive (R-) forms of the molecule. Escitalopram, on the other hand, consists only of the active S-enantiomer.


Q: Can Citalopram cause problems with memory or cognitive function?

Official product information notes that the medication may interfere with cognitive function. Post-marketing experience has included reports of difficulty with thinking, concentration, and memory.

Advertisements

How should Lowdep (Citalopram) be stored and disposed of?

Official Storage and Disposal Profile

Storage Requirements

Citalopram must be kept in the container it came in and the container must be tightly closed. Store the medication at room temperature, ensuring it is protected from excess heat and excess moisture; for example, it should not be stored in the bathroom. To prevent accidental poisoning, the medication must be stored out of the sight and reach of children and pets, placed in a safe location that is up and away.

Disposal Instructions

The safest method for disposal of unused or expired Citalopram is through a formal drug take-back program or mail-back service. Citalopram is not on the official flush list; therefore, it must not be flushed down the toilet or poured down a sink. If a take-back program is unavailable, drugs can be disposed of in the household trash only after being mixed with an undesirable substance like dirt or used coffee grounds and sealed in a container to prevent leakage.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lowdep (Citalopram) found in:

A-Z Index: